PTH and PTHrP Peptide Hormones: Dual Roles in Bone Formation and Breakdown
Review of how parathyroid hormone (PTH) and PTH-related protein (PTHrP) share a common receptor but exert complex, sometimes opposing effects on bone through their amino-terminal peptide domains — informing osteoporosis drug design.
Quick Facts
What This Study Found
PTH and PTHrP share amino-terminal domain identity and PTH1R receptor activation but have distinct physiological and pharmacological roles in bone. Intermittent PTH builds bone (anabolic) while continuous PTH breaks it down (catabolic). Genetic models clarify mechanism distinctions.
Key Numbers
PTH1R shared receptor; cAMP-PKA pathway; teriparatide (PTH) and abaloparatide (PTHrP); intermittent = anabolic, continuous = catabolic
How They Did This
Narrative review of PTH and PTHrP bone biology using genetic model data to distinguish their physiological and pharmacological roles through PTH1R signaling.
Why This Research Matters
Osteoporosis affects 200+ million people. Understanding how related peptide hormones build vs break bone enables design of better anabolic bone drugs — exemplified by teriparatide (PTH fragment) and abaloparatide (PTHrP-based).
The Bigger Picture
Understanding the nuanced biology of closely related peptide hormones is essential for drug design. The PTH/PTHrP story shows how dosing pattern (intermittent vs continuous) can flip a peptide's effect from beneficial to harmful — a principle applicable to other peptide drugs.
What This Study Doesn't Tell Us
Review based heavily on genetic models that may not fully replicate human bone physiology. PTH1R signaling complexity not fully resolved. Clinical implications of some genetic findings unclear.
Questions This Raises
- ?Can next-generation PTH/PTHrP analogs provide even better bone building?
- ?Why does intermittent vs continuous PTH have opposite bone effects?
- ?Could oral PTH peptide analogs replace injectable teriparatide?
Trust & Context
- Key Stat:
- Same receptor, opposite effects PTH builds bone when given intermittently but breaks it down when continuous — dosing pattern completely reverses the peptide hormone's bone effect
- Evidence Grade:
- Not applicable (review). Based on genetic models and established clinical pharmacology of approved drugs.
- Study Age:
- Published 2021. PTH-based osteoporosis drugs (teriparatide, abaloparatide) are established treatments.
- Original Title:
- Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R.
- Published In:
- Endocrine reviews, 42(4), 383-406 (2021)
- Authors:
- Martin, T John, Sims, Natalie A, Seeman, Ego
- Database ID:
- RPEP-05582
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do PTH drugs build bone?
When PTH is given as a daily injection (intermittent), it stimulates bone-forming cells (osteoblasts) more than bone-breaking cells. This net effect builds new bone. Continuous PTH exposure has the opposite effect, which is why daily injections — not continuous infusion — are used.
What is the difference between teriparatide and abaloparatide?
Teriparatide (Forteo) is a fragment of human PTH. Abaloparatide (Tymlos) is based on PTHrP. Both build bone through the same receptor but with slightly different signaling. Abaloparatide may cause less calcium elevation. Both are daily injectable osteoporosis treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05582APA
Martin, T John; Sims, Natalie A; Seeman, Ego. (2021). Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R.. Endocrine reviews, 42(4), 383-406. https://doi.org/10.1210/endrev/bnab005
MLA
Martin, T John, et al. "Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R.." Endocrine reviews, 2021. https://doi.org/10.1210/endrev/bnab005
RethinkPeptides
RethinkPeptides Research Database. "Physiological and Pharmacological Roles of PTH and PTHrP in ..." RPEP-05582. Retrieved from https://rethinkpeptides.com/research/martin-2021-physiological-and-pharmacological-roles
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.